Cream shows promise for genital vitiligo in early trial

NCT ID NCT05750823

Completed Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a cream called ruxolitinib (Opzelura) on 49 people with nonsegmental vitiligo affecting the genitals. Participants applied the cream twice daily for up to 48 weeks to see if it made the white patches less noticeable. The study measured success based on patient reports of how noticeable the vitiligo was compared to before treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ruxolitinib cream (Opzelura)
What this could lead to: If successful, this could offer a topical treatment option for genital vitiligo, potentially reducing the appearance of white patches.
What could go wrong: This is a small, early-phase trial with no placebo group, so results may not be conclusive. Side effects like skin irritation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NONSEGMENTAL VITILIGO WITH GENITAL INVOLVEMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NONSEGMENTAL VITILIGO WITH GENITAL INVOLVEMENT

Contacts and locations

Locations

Apex Clinical Research Center

Mayfield, Ohio, 44124, United States
Austin Institute For Clinical Research Aicr Pflugerville

Pflugerville, Texas, 78660, United States
Center For Dermatology Clinical Research, Inc

Fremont, California, 94538, United States
Centre Hospitalier Universitaire de Bordeaux

Bordeaux, 33075, France
Chu Nice Hopital Archet 2

Nice, 06202, France
Dermatology Research Institute

Calgary, Alberta, T2J 7E1, Canada
Hamzavi Dermatology

Fort Gratiot, Michigan, 48059-3526, United States
Hopital Henri Mondor Service de Dermatologie

Créteil, 94000, France
Innovative Dermatology: Legacy Medical Village

Plano, Texas, 75024-4319, United States
Research Toronto

Toronto, Ontario, M3H 5Y8, Canada
Simcomed Health Ltd

Barrie, Ontario, L4M 7G1, Canada
Skin Centre For Dermatology

Peterborough, Ontario, K9J 5K2, Canada
Vitiligo & Pigmentation Institute of Southern California

Los Angeles, California, 90036, United States